

KOLEK M.¹, PECHÁČEK J.¹, POUR M.², NOVÁK J.²

¹ OAKS Consulting s.r.o, Prague, Czech Republic

² ROCHE, s.r.o., Prague, Czech Republic

OBJECTIVES

As of January **2022**, a new unique pathway for reimbursement of orphan drugs was opened in the Czech Republic. After one year, an evaluation of its effects is in order. We therefore set out to:

- To determine the influence of inclusion of governmental and societal perspectives on the results of health technology assessment of orphan drugs in the Czech Republic.
- To estimate the total number of patients who are expected to be treated with the orphan drugs.
- To estimate the expected cost of the orphan drugs in the context of the total expenditure of the Czech healthcare system on drugs.

METHODS

Public documentation of **100%** administrative proceedings for the reimbursement of orphan drugs initiated in **2022** was reviewed. Most up-to-date information was collected for each intervention and indication, where available:

ICER and net budget impact from healthcare, governmental and societal perspectives, estimated costs of the orphan drugs, number of patients expected to be treated Data was described statistically and contrasted with public information on total drug-related expenditures of the Czech healthcare system


RESULTS

Across all evaluable proceedings (**N=19**), **ICER** from governmental perspective was lower than **ICER** from the payers' perspective by **3.1%** and **ICER** from societal perspective was lower by **22.8%**. Total of **1,600 - 2,300** patients are expected to be treated by these orphan drugs each year. Total expenditures for these orphan drugs represent **10%** of the projected drug expenditures of the whole Czech healthcare system five years from now.

CONCLUSION

The new pathway towards reimbursement for orphan drugs in the Czech Republic was utilized in **19** cases in the first year. Generally, inclusion of governmental and societal perspective resulted in lower **ICER**, and budget impact thus increased the value of these drugs. Expenditures for these orphan drugs are expected to account for **10%** of the overall spending of the Czech healthcare system on drugs

Relative reduction in ICER from the governmental perspective versus the payers' perspective



Relative reduction in ICER from a societal perspective versus the payers' perspective

